"Disclosing amyloid imaging results" a Featured Research Session at the Alzheimer's Association International Conference
Biomarkers are seen as critical tools for assessing risk and tracking disease progress in Alzheimer’s disease. However, their successful integration into clinical practice and clinical trials with preclinical populations will require skilled communications of complex, ambiguous information, as well as better understanding of the psychological and behavioral impact of these communications on patients and family members. This multidisciplinary panel will describe both ongoing and proposed interventions in which biomarker information is disclosed to populations at “imminent” risk (i.e., within the next five years) of developing clinically expressed Alzheimer’s disease.
Panelists include Jason Karlawish, MD from the University of Pennsylvania; Robert Green, MD from Harvard University; Scott Roberts, PhD from University of Michigan; Jennifer Lingler, PhD from Pittsburgh University; and Reisa Sperling, MD from Harvard University.
The AAIC is the yearly international meeting of Alzheimer's Disease researchers. This year's meeting will be held in Vancouver, British Columbia, Canada.